European Medicines Agency approves axitinib and pazopanib

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has approved axitinib and pazopanib for patients with advanced renal cell carcinoma and selected subtypes of advanced soft tissue sarcoma. While axitinib should only be administered by a physician with experience in anticancer therapies, the CHMP remains steadfast that the benefit-to-risk ratio for this drug is favourable enough to warrant its recommendation. Pazopanib is proposed as the first line of treatment for patients afflicted with advanced renal cell carcinoma. More information on this study can be found here.